What is HC Wainwright's Forecast for KPTI FY2024 Earnings?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) - Stock analysts at HC Wainwright reduced their FY2024 earnings per share (EPS) estimates for shares of Karyopharm Therapeutics in a report issued on Wednesday, January 15th. HC Wainwright analyst E. White now forecasts that the company will post earnings per share of ($1.10) for the year, down from their prior forecast of ($1.06). HC Wainwright has a "Buy" rating and a $7.00 price target on the stock. The consensus estimate for Karyopharm Therapeutics' current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Karyopharm Therapeutics' Q4 2024 earnings at ($0.35) EPS, Q1 2025 earnings at ($0.31) EPS, Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.33) EPS, FY2025 earnings at ($1.21) EPS, FY2026 earnings at ($0.70) EPS and FY2027 earnings at ($0.04) EPS.

KPTI has been the subject of several other research reports. Piper Sandler upped their price target on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an "overweight" rating in a research report on Wednesday, November 6th. StockNews.com cut shares of Karyopharm Therapeutics from a "buy" rating to a "hold" rating in a report on Friday, November 22nd. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $5.00.

Karyopharm Therapeutics Trading Down 5.5 %

KPTI stock traded down $0.04 during trading on Friday, reaching $0.66. The stock had a trading volume of 571,600 shares, compared to its average volume of 819,536. The firm has a market cap of $83.30 million, a PE ratio of -0.58 and a beta of 0.07. The stock's 50 day moving average is $0.75 and its two-hundred day moving average is $0.81. Karyopharm Therapeutics has a 52 week low of $0.58 and a 52 week high of $1.95.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.26) earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.01. The company had revenue of $38.78 million for the quarter, compared to the consensus estimate of $37.86 million. During the same quarter last year, the company earned ($0.30) EPS.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. AQR Capital Management LLC raised its position in shares of Karyopharm Therapeutics by 494.5% during the 2nd quarter. AQR Capital Management LLC now owns 748,020 shares of the company's stock valued at $649,000 after purchasing an additional 622,194 shares during the period. Cubist Systematic Strategies LLC purchased a new stake in Karyopharm Therapeutics in the 2nd quarter worth $494,000. Geode Capital Management LLC raised its holdings in Karyopharm Therapeutics by 3.3% during the third quarter. Geode Capital Management LLC now owns 1,355,392 shares of the company's stock valued at $1,125,000 after acquiring an additional 43,856 shares during the period. GSA Capital Partners LLP lifted its position in shares of Karyopharm Therapeutics by 80.6% in the third quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company's stock valued at $1,474,000 after acquiring an additional 792,283 shares in the last quarter. Finally, Acadian Asset Management LLC bought a new position in shares of Karyopharm Therapeutics in the second quarter worth about $167,000. 66.44% of the stock is currently owned by institutional investors.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).